Acurx Pharmaceuticals Net Income

The latest net income for ACXP is $-10B as of June 2026. That compares with $-5.1B in the prior-year period — down 96.3% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Acurx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACXP's net income moved from $-5.1B to $-10B — a 96.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acurx Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, ACXP currently prints $-10B for net income, while the sector average sits near $16B. That is roughly 162.0% below the sector mean. Large gaps often invite a closer look at Acurx Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-10B for ACXP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting ACXP's net income ($-10B), review year-over-year change from $-5.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.